J. Stumpf

Pharmacokinetic and Pharmacodynamic Effects of Elinogrel: Results of the Platelet Function Substudy From the Intravenous and Oral Administration of Elinogrel to Evaluate Tolerability and Efficacy in Nonurgent Percutaneous Coronary Intervention Patients (INNOVATE-PCI) Trial

Sunil V. Rao, J. Wójcik, F. Neumann, 2012, Circulation. Cardiovascular Interventions.

Adiponectin in coronary heart disease and newly diagnosed impaired glucose tolerance

V. Lodwig, R. Dörr, O. Schnell, 2013, Diabetes & vascular disease research.

High-dose 7-hexanoyltaxol-eluting stent with polymer sleeves for coronary revascularization: one-year results from the SCORE randomized trial.

S. Silber, C. Di Mario, A. Lansky, 2004, Journal of the American College of Cardiology.

Oral glucose tolerance test and HbA1c for diagnosis of diabetes in patients undergoing coronary angiography the Silent Diabetes Study

L. Heinemann, V. Lodwig, U. Hoffmann, 2011, Diabetologia.

THE CLL‐RT1 TRIAL: A MULTICENTER PHASE‐2 TRIAL OF ZANUBRUTINIB, A BTK INHIBITOR, PLUS TISLELIZUMAB, A PD‐1 INHIBITOR, FOR PATIENTS WITH RICHTER TRANSFORMATION

M. Hallek, P. Staber, K. Kreuzer, 2021, Hematological Oncology.

Pharmacokinetic and Pharmacodynamic Effects of Elinogrel: Results of the Platelet Function Substudy From the Intravenous and Oral Administration of Elinogrel to Evaluate Tolerability and Efficacy in Nonurgent Percutaneous Coronary Intervention Patients (INNOVATE-PCI) Trial

J. Wójcik, F. Neumann, R. Harrington, 2012, Circulation. Cardiovascular interventions.